Capricor Therapeutics Inc
F:4LN2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Capricor Therapeutics Inc
F:4LN2
|
US |
Intrinsic Value
The intrinsic value of 
Capricor Therapeutics Inc (4LN2) under the Base Case is 17.624 EUR per share.
Compared with the current market price of 5.162 EUR, the stock appears
Undervalued by 71% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Capricor Therapeutics Does
Capricor Therapeutics is a biotechnology company that develops cell-based medicines for serious diseases, with a main focus on heart and muscle disorders. Its lead program is deramiocel, an allogeneic cardiosphere-derived cell therapy being studied for Duchenne muscular dystrophy, a genetic disease that weakens muscles over time. The company also works on exosome-based therapies, which use tiny particles released by cells as a way to deliver treatment signals.
- Headquarters
- United States of America US
- Employees
- 231
- IPO date
- Jun 4, 2002
Capricor Therapeutics has no economic moat
Capricor Therapeutics Inc lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.
Read the full moat analysis
Revenue & Expenses Breakdown
Capricor Therapeutics Inc
Earnings Waterfall
Capricor Therapeutics Inc
The intrinsic value for Capricor Therapeutics Inc (4LN2) under the Base Case is 17.624 EUR.
Compared with the current market price of 5.162 EUR, the stock appears Undervalued by 71% .